Biotech CEO Sisterhood: A leadership series discussion on building an effective board, best practices for running meetings, hiring talent, and decision making

Sisterhood editorial board members Daphne Zohar (Seaport Therapeutics) and Luba Greenwood (Gallop Oncology) share their experiences about what types of leaders do and don't make good board members, how to efficiently manage meetings and discussions, and general leadership skills of running a company.

Biographies

Daphne Zohar is the Founder, CEO and Board Member of Seaport Therapeutics. Previously, she was the Founder, CEO and Board Member of PureTech Health (Nasdaq: PRTC), where she also co-founded PureTech’s entities, including Karuna Therapeutics (Nasdaq: KRTX), which was acquired by Bristol Myers Squibb for $14 billion. A successful entrepreneur, Ms. Zohar created PureTech, assembling a leading team to help implement her vision for the company, and was a key driver in fundraising, business development and establishing the underlying programs and platforms that resulted in PureTech’s productive R & D engine, which led to 28 new medicines being advanced via its Wholly Owned Pipeline and Founded Entities, including Cobenfy (KarXT) that has just received US FDA approval. PureTech’s track record of clinical success is approximately six times better than the industry average and 80 percent of the clinical studies run by PureTech and its Founded Entities have been successful

Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, Goldman Sachs, Fierce Pharma, BioWorld, MIT Technology Review, The Boston Globe and Scientific American. She serves on the BIO (Biotechnology Innovation Organization) Board Executive Committee as well as the Health Section Committee. Ms. Zohar is a member of the Duke-Margolis Center Policy Roundtable on the Inflation Reduction Act (IRA) and the Health Affairs IRA Observatory.

Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of experience in the healthcare and tech sectors. She has served as CEO of multiple biotechnology companies, including currently serving as CEO of Gallop Oncology and most recently as CEO and Board Chair of Kojin Tx. She has founded and served as Managing Partner of the Dana Farber Cancer Institute venture fund, Binney Street Capital. She is also entrepreneur-in residence at Puretech where she plays a key role in PureTech’s oncology programs.

Ms. Greenwood has previously served in leadership roles at Google (Verily) and Roche. Luba has led $15B+ in deals and investments across multiple therapeutic areas, diagnostics, life sciences and tech sectors globally. She is a Thought Leader for

the New England Journal of Medicine Catalyst and serves on the Investor Committee for the National Cancer Institute.

Ms. Greenwood has extensive board experience globally and serves on public and private boards, across multiple industries, including In8Bio (INAB), BenchSci, Stalicla, Abcam (ABCAM), Traws Pharma (TRAW), Closed Loop Medicine, and Massachusetts Biotechnology Council (MassBio). Ms. Greenwood began her career practicing law at WilmerHale and is an expert in regulatory, securities, and intellectual property matters. She also served as a lecturer at Harvard University in the School of Engineering and Applied Sciences.